<div id="readability-page-1"><p>Assenagon Asset Management S.A. decreased its position in shares of  Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 73.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor  owned 5,588 shares of the medical research company's stock after selling 15,248 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Quest Diagnostics were worth $1,065,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Quest Diagnostics</strong> alerts:</span></p></div><ul><li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li></ul><p>Other hedge funds and other institutional investors have also bought and sold shares of the company. Oak Thistle LLC grew its position in  Quest Diagnostics by 119.7% during the 3rd quarter. Oak Thistle LLC now owns 3,833 shares of the medical research company's stock worth $730,000 after purchasing an additional 2,088 shares during the last quarter.  Aaron Wealth Advisors LLC purchased a new position in  Quest Diagnostics during the third quarter valued at approximately $1,452,000.  GAMMA Investing LLC boosted its holdings in  Quest Diagnostics by 17.4% during the third quarter. GAMMA Investing LLC now owns 3,511 shares of the medical research company's stock worth $669,000 after buying an additional 520 shares in the last quarter.  Hobart Private Capital LLC acquired a new stake in shares of  Quest Diagnostics during the 3rd quarter valued at about $564,000.  Finally, Caldwell Trust Co purchased a new stake in shares of  Quest Diagnostics in the second quarter valued at approximately $346,000. Institutional investors own  88.06% of the company's stock. </p><h2>Quest Diagnostics Stock Up 0.5%</h2><p>Shares of NYSE:DGX opened at $175.92 on Thursday. The stock has a 50-day simple moving average of $182.79 and a 200-day simple moving average of $179.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. Quest Diagnostics Incorporated has a 1 year low of $148.70 and a 1 year high of $197.55. The stock has a market capitalization of $19.57 billion, a P/E ratio of 20.65, a PEG ratio of 2.36 and a beta of 0.62. </p><ul><li>LifeMD Shares Come Back to Life on GLP-1 Business Growth </li></ul><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the prior year, the firm earned $2.30 earnings per share. The business's quarterly revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS.  Equities analysts forecast that  Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year. </p><h2>Quest Diagnostics Announces Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics's payout ratio is presently 37.56%. </p><h2>Insider Buying and Selling</h2><ul><li>Exact Sciences Serves Investors Exactly What They Wished For </li></ul><p>In other news, SVP Mark E. Delaney sold 7,946 shares of the firm's stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the transaction, the senior vice president directly owned 7,530 shares of the company's stock, valued at approximately $1,410,745.50. This trade represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, SVP Michael E. Prevoznik sold 227 shares of the company's stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president directly owned 38,117 shares of the company's stock, valued at approximately $7,170,951.21. This represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,998 shares of company stock valued at $12,631,382 in the last ninety days. Insiders own  8.16% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several analysts recently commented on the company. Barclays boosted their price target on Quest Diagnostics from $190.00 to $195.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 22nd. UBS Group raised their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 17th. Leerink Partners increased their price target on shares of Quest Diagnostics from $203.00 to $210.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, October 21st. Weiss Ratings  reissued a &#34;buy (b-)&#34; rating on shares of Quest Diagnostics in a research report on Monday. Finally, Wall Street Zen lowered Quest Diagnostics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. One analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $197.27.</p><p><b>Read Our Latest Stock Report on DGX</b></p><h2>Quest Diagnostics Profile</h2> (Free Report)<p>Quest Diagnostics <span>NYSE: DGX<span></span></span> is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.  </p><p>Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Quest Diagnostics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2><p>Before you consider Quest Diagnostics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Assenagon Asset Management S.A. reduced its stake in Quest Diagnostics Incorporated by 73.2% in Q3, now holding 5,588 shares worth $1,065,000. Other institutional investors also adjusted their positions. Quest Diagnostics reported Q3 earnings of $2.60 per share, beating estimates, with revenue up 13.2% year-over-year. The company announced a quarterly dividend of $0.80 per share. Insiders sold shares worth $12.63 million in the last 90 days. The stock opened at $175.92 with a market cap of $19.57 billion.</p>

Assenagon Asset Management S.A. Lowers Stake in Quest Diagnostics Incorporated $DGX